OmniSeq receives New York State CLEP approval

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program approval for its OmniSeq Comprehensive panel, a 144 gene, pan-cancer, next-generation sequencing tumor profiling diagnostic panel to guide oncology treatment decision-making.

“OmniSeq is proud to receive New York State CLEP approval for OmniSeq Comprehensive. CLEP is the highest standard of Clinical Laboratory Improvement Amendments laboratory validation,” said Carl Morrison, president and chief scientific officer of OmniSeq and executive director of the Roswell Park Center for Personalized Medicine.

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login